{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:12:24Z","timestamp":1758759144802,"version":"3.44.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,24]]},"DOI":"10.7759\/cureus.93099","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T11:44:28Z","timestamp":1758714268000},"source":"Crossref","is-referenced-by-count":0,"title":["Knowledge, Attitudes, and Practices Regarding Biosimilars Among Pharmacists and Physicians in Saudi Arabia: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Abdulrhman","family":"Alanizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranad","family":"Babalghaith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Qubaiban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Hattan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alnuhait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Al Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1071188","article-title":"Biosimilar regulation in the EU","volume":"8","author":"Kurki P","year":"2015","unstructured":"Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol. 2015, 8:649-59. 10.1586\/17512433.2015.1071188","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5010-884","article-title":"Biosimilars are here: a hospital pharmacist\u2019s guide to educating health care professionals on biosimilars","volume":"50","author":"Jarrett S","year":"2015","unstructured":"Jarrett S, Dingermann T. Biosimilars are here: a hospital pharmacist\u2019s guide to educating health care professionals on biosimilars. Hosp Pharm. 2015, 50:884-93. 10.1310\/hpj5010-884","journal-title":"Hosp Pharm"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0020-y","article-title":"Development and regulation of biosimilars: current status and future challenges","volume":"27","author":"Tsiftsoglou AS","year":"2013","unstructured":"Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013, 27:203-11. 10.1007\/s40259-013-0020-y","journal-title":"BioDrugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart DC","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?. Front Pharmacol. 2019, 10:279. 10.3389\/fphar.2019.00279","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.022","article-title":"Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data","volume":"38","author":"Sugiyama N","year":"2016","unstructured":"Sugiyama N, Kawahito Y, Fujii T, Atsumi T, Murata T, Morishima Y, Fukuma Y. Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data. Clin Ther. 2016, 38:1359-1375.e1. 10.1016\/j.clinthera.2016.03.022","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex277","article-title":"Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm","volume":"56","author":"Schulze-Koops H","year":"2017","unstructured":"Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017, 56:iv30-48. 10.1093\/rheumatology\/kex277","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1188\/18.CJON.S1.5-12","article-title":"Exploring the history, science, and progress","volume":"22","author":"Tariman JD","year":"2018","unstructured":"Tariman JD. Exploring the history, science, and progress. Clin J Oncol Nurs. 2018, 22:5-12. 10.1188\/18.CJON.S1.5-12","journal-title":"Clin J Oncol Nurs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0431-5","article-title":"Awareness, knowledge, and perceptions of biosimilars among specialty physicians","volume":"33","author":"Cohen H","year":"2017","unstructured":"Cohen H, Beydoun D, Chien D, et al.. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017, 33:2160-72. 10.1007\/s12325-016-0431-5","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2235277","article-title":"The landscape of biosimilars in Saudi Arabia: preparing for the next decade","volume":"23","author":"Almutairi AR","year":"2023","unstructured":"Almutairi AR, Al-Samil AM, Alsayyari A, Yousef CC, Khan MA, Alhamdan HS, Al-Jedai A. The landscape of biosimilars in Saudi Arabia: preparing for the next decade. Expert Opin Biol Ther. 2023, 23:679-88. 10.1080\/14712598.2023.2235277","journal-title":"Expert Opin Biol Ther"},{"key":"ref10","article-title":"Physicians\u2019 knowledge and awareness about biosimilars in Saudi Arabia: what is imperative to know??","volume":"22","author":"Almalki ZS","year":"2020","unstructured":"Almalki ZS, Iqbal MS, Alossaimi MA, et al.. Physicians\u2019 knowledge and awareness about biosimilars in Saudi Arabia: what is imperative to know??. J Young Pharm. 2020, 22:280-4.","journal-title":"J Young Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2020.11.008","article-title":"Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia","volume":"28","author":"Omair MA","year":"2020","unstructured":"Omair MA, Alhawassi T, Alwaihibi M, et al.. Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia. Saudi Pharm J. 2020, 28:1827-9. 10.1016\/j.jsps.2020.11.008","journal-title":"Saudi Pharm J"},{"key":"ref12","article-title":"Evaluation of physicians\u2019 practices, attitude and perceptions towards biosimilars usage among patients","volume":"24","author":"Alahmari AK","year":"2020","unstructured":"Alahmari AK, Almalki ZS, Shahid I, et al.. Evaluation of physicians\u2019 practices, attitude and perceptions towards biosimilars usage among patients. Med Sci. 2020, 24:4410-7.","journal-title":"Med Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.22.287936","article-title":"National medicines policy development, Saudi Arabia","volume":"100","author":"Almoteiry K","year":"2022","unstructured":"Almoteiry K, Alharf A, Al Hammad B, et al.. National medicines policy development, Saudi Arabia. Bull World Health Organ. 2022, 100:511-9. 10.2471\/BLT.22.287936","journal-title":"Bull World Health Organ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref15","article-title":"Biosimilars: A Global Roadmap for Policy Sustainability","author":"Wilsdon T","year":"2022","unstructured":"Wilsdon T, Pistollato M, Ross-Stewart K, Saada R, Barquin P. Biosimilars: A Global Roadmap for Policy Sustainability. Charles River Associates, London, UK; 2022."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v15i1.5922","article-title":"Factors that influence healthcare professionals\u2019 intentions towards biosimilars","volume":"15","author":"Qahtani MA","year":"2024","unstructured":"Qahtani MA, Al-Jedai A, Wertheimer A. Factors that influence healthcare professionals\u2019 intentions towards biosimilars. Innov Pharm. 2024, 15:10.24926\/iip.v15i1.5922","journal-title":"Innov Pharm"},{"key":"ref17","article-title":"Knowledge and attitude of pharmacists about biosimilar medications in Saudi Arabia","volume":"7","author":"Alahmari AK","year":"2021","unstructured":"Alahmari AK, Almalki ZS, Shahid Iqbal M, et al.. Knowledge and attitude of pharmacists about biosimilar medications in Saudi Arabia. Int J Pharm Investig. 2021, 7:123-6.","journal-title":"Int J Pharm Investig"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/27550834231167049","article-title":"Assessment of community pharmacists' knowledge of the differences between generic drugs and biosimilars: a pilot cross-sectional study","volume":"7","author":"Awada S","year":"2023","unstructured":"Awada S, Sayah R, Mansour M, Nabhane C, Hatem G. Assessment of community pharmacists' knowledge of the differences between generic drugs and biosimilars: a pilot cross-sectional study. J Med Access. 2023, 7:27550834231167049. 10.1177\/27550834231167049","journal-title":"J Med Access"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.22377\/ajp.v14i03.3757","article-title":"Pharmacists' awareness and perceptions of biosimilars in Saudi Arabia","volume":"14","author":"Iqbal M","year":"2020","unstructured":"Iqbal M. Pharmacists' awareness and perceptions of biosimilars in Saudi Arabia. Asian J Pharm. 2020, 14:10.22377\/ajp.v14i03.3757","journal-title":"Asian J Pharm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/00185787221138007","article-title":"An institutional guide for formulary decisions of biosimilars","volume":"58","author":"Ismail S","year":"2023","unstructured":"Ismail S, Abu Esba L, Khan M, Al-Abdulkarim H, Modimagh H, Yousef C. An institutional guide for formulary decisions of biosimilars. Hosp Pharm. 2023, 58:38-48. 10.1177\/00185787221138007","journal-title":"Hosp Pharm"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2021.10.012","article-title":"Perception of biosimilar biologics and non-medical prescription switching among rheumatologists: a Saudi Society for Rheumatology initiative","volume":"30","author":"Omair MA","year":"2022","unstructured":"Omair MA, Almadany R, Omair MA, Al Rayes H, Almalag HM, Alshamsan A. Perception of biosimilar biologics and non-medical prescription switching among rheumatologists: a Saudi Society for Rheumatology initiative. Saudi Pharm J. 2022, 30:39-44. 10.1016\/j.jsps.2021.10.012","journal-title":"Saudi Pharm J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/1049732312452938","article-title":"Beyond PICO: the SPIDER tool for qualitative evidence synthesis","volume":"22","author":"Cooke A","year":"2012","unstructured":"Cooke A, Smith D, Booth A. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 2012, 22:1435-43. 10.1177\/1049732312452938","journal-title":"Qual Health Res"},{"key":"ref23","article-title":"Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching","volume":"15","author":"Somaily M","year":"2021","unstructured":"Somaily M, Alahmari H, Abbag W, et al.. Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching. GaBI J. 2021, 15:68-71.","journal-title":"GaBI J"},{"key":"ref24","article-title":"Biosimilars in rheumatic diseases: regulatory guidelines, efficacy and safety implications in Saudi Arabia","volume":"2","author":"Halabi H","year":"2019","unstructured":"Halabi H, Al Zahrani Z, Al Swailem R, et al.. Biosimilars in rheumatic diseases: regulatory guidelines, efficacy and safety implications in Saudi Arabia. Open Rheumatol J. 2019, 2:313-22.","journal-title":"Open Rheumatol J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/biom9020057","article-title":"Evaluation of Physicians\u2019 knowledge and attitudes towards biosimilars in Russia and issues associated with their prescribing","volume":"9","author":"Karateev D","year":"2019","unstructured":"Karateev D, Belokoneva N. Evaluation of Physicians\u2019 knowledge and attitudes towards biosimilars in Russia and issues associated with their prescribing. Biomolecules. 2019, 9:57. 10.3390\/biom9020057","journal-title":"Biomolecules"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1571296","article-title":"Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States","volume":"35","author":"Teeple A","year":"2019","unstructured":"Teeple A, Ellis LA, Huff L, et al.. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019, 35:611-7. 10.1080\/03007995.2019.1571296","journal-title":"Curr Med Res Opin"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.06.013","article-title":"Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: a survey of physicians and pharmacists in Ireland","volume":"88","author":"O'Callaghan J","year":"2017","unstructured":"O'Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, Griffin BT. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: a survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017, 88:252-61. 10.1016\/j.yrtph.2017.06.013","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00341-w","article-title":"Perspectives of hospital pharmacists towards biosimilar medicines: a survey of Polish pharmacy practice in general hospitals","volume":"33","author":"Paw\u0142owska I","year":"2019","unstructured":"Paw\u0142owska I, Paw\u0142owski L, Krzy\u017caniak N, Koci\u0107 I. Perspectives of hospital pharmacists towards biosimilar medicines: a survey of Polish pharmacy practice in general hospitals. BioDrugs. 2019, 33:183-91. 10.1007\/s40259-019-00341-w","journal-title":"BioDrugs"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.1.102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review","volume":"25","author":"Leonard E","year":"2019","unstructured":"Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019, 25:102-12. 10.18553\/jmcp.2019.25.1.102","journal-title":"J Manag Care Spec Pharm"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S104891","article-title":"Patient attitudes and understanding about biosimilars: an international cross-sectional survey","volume":"10","author":"Jacobs I","year":"2016","unstructured":"Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016, 10:937-48. 10.2147\/PPA.S104891","journal-title":"Patient Prefer Adherence"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00440-z","article-title":"European stakeholder learnings regarding biosimilars: part II-improving biosimilar use in clinical practice","volume":"34","author":"Barbier L","year":"2020","unstructured":"Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: part II-improving biosimilar use in clinical practice. BioDrugs. 2020, 34:797-808. 10.1007\/s40259-020-00440-z","journal-title":"BioDrugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70365-1","article-title":"Regulatory and clinical considerations for biosimilar oncology drugs","volume":"15","author":"Bennett CL","year":"2014","unstructured":"Bennett CL, Chen B, Hermanson T, et al.. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014, 15:e594-605. 10.1016\/S1470-2045(14)70365-1","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30485-X","article-title":"Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated policy review from the Southern Network on Adverse Reactions","volume":"21","author":"Bennett CL","year":"2020","unstructured":"Bennett CL, Schoen MW, Hoque S, et al.. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated policy review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020, 21:e575-88. 10.1016\/S1470-2045(20)30485-X","journal-title":"Lancet Oncol"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190147","article-title":"Policies for biosimilar uptake in Europe: an overview","volume":"12","author":"Moorkens E","year":"2017","unstructured":"Moorkens E, Vulto AG, Huys I, et al.. Policies for biosimilar uptake in Europe: an overview. PLOS ONE. 2017, 12:e0190147.","journal-title":"PLOS ONE"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.5688\/ajpe81357","article-title":"A framework for integrating biosimilars into the didactic core requirements of a Doctor of Pharmacy curriculum","volume":"81","author":"Li E","year":"2017","unstructured":"Li E, Liu J, Ramchandani M. A framework for integrating biosimilars into the didactic core requirements of a Doctor of Pharmacy curriculum. Am J Pharm Educ. 2017, 81:57. 10.5688\/ajpe81357","journal-title":"Am J Pharm Educ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397469-knowledge-attitudes-and-practices-regarding-biosimilars-among-pharmacists-and-physicians-in-saudi-arabia-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T11:44:30Z","timestamp":1758714270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397469-knowledge-attitudes-and-practices-regarding-biosimilars-among-pharmacists-and-physicians-in-saudi-arabia-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.93099","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}